Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 4, 2010, Pages 347-353

  Harris, Elana ^a   Eng, Hing Yee ^b   KowatC H , Robert ^a   Delgado, Sergio V ^a   Saldaña, Shannon N ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; GUANFACINE; MACROGOL 3350; METHYLPHENIDATE; MIRTAZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SERTRALINE;

ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEDTIME DOSAGE; BEHAVIOR DISORDER; BEHAVIORAL DISINHIBITION; CASE REPORT; CAUCASIAN; CHILD; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ECHOLALIA; EYELID REFLEX; FEVER; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; HISPANIC; HUMAN; HYPERSENSITIVITY; IRRITABILITY; KOREA; LEARNING DISORDER; LOW DRUG DOSE; MALE; OBSESSIVE COMPULSIVE DISORDER; ODOR; PHENOTYPE; PSYCHOLOGICAL RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SKIN ABRASION; SOUND; TASTE; TIC; TOUCH; WEIGHT GAIN;

ARYL HYDROCARBON HYDROXYLASES; CHILD; CYTOCHROME P-450 CYP2D6; FLUVOXAMINE; HUMANS; IMPULSIVE BEHAVIOR; INHIBITION (PSYCHOLOGY); MALE; OBSESSIVE-COMPULSIVE DISORDER; PHARMACOGENETICS; SEROTONIN UPTAKE INHIBITORS;

EID: 77956399253     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0126     Document Type: Article

References (31)

1. Allin MP, Marshall N, Schulze K, Walshe M, Hall MH, Picchioni M, Murray RM, McDonald C: A functional MRI study of verbal fluency in adults with bipolar disorder and their unaffected relatives. Psychol Med 11:1-11, 2010.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Revised. (DSM-IV). Washington, DC: American Psychiatric Press; 1994.
3. Baxter LR Jr., Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH, Fairbanks L: Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 145:1560-1563, 1988.
4. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluvox-amine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214, 1993.
5. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265, 1992.
6. de Leon J: The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 59:81-89, 2009.
7. de Leon J, Arranz MJ, Ruano G: Pharmacogenetic testing in psychiatry: A review of features and clinical realities. Clin Lab Med 28:599-617, 2008.
8. Fleishaker JC, Hulst LK: A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and flu-voxamine. Eur J Clin Pharmacol 46:35-39, 1994.
9. Garland EJ, Baerg EA: A motivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol 11:181-186, 2001.
10. Hemeryck A, Belpaire FM: Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update. Curr Drug Metab 3:13-37, 2002.
11. Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, Hughes J, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie G, March J: Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 45:1404-1411, 2006. (Pubitemid 44900913)
12. Leonard HL, March J, Rickler KC, Allen AJ: Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:725-736, 1997.
13. Leslie LK, Newman TB, Chesney PJ, Perrin JM: The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics 116:195-204, 2005.
14. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807-820, 2004. (Pubitemid 39079667)
15. Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S, Bellodi L, Smeraldi E, Fazio F: [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry 166:244-250, 1995.
16. Prows CA, Nick TG, Saldana SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks A, Slauser TA: Drug-metabolizing enzyme genotypes and aggressive behaviour treatment response in hospitalized pedi-atric psychiatric patients. J Child Adolesc Psychopharmacol 19: 385-394, 2009.
17. Rapoport JL: Recent advances in obsessive-compulsive disorder. Neuropsychopharmacology 5:1-10, 1991.
18. Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR, Fischman AJ: Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51:62-70, 1994.
19. Reinblatt SP, DosReis S, Walkup JT, Riddle MA: Activation adverse events induced by the selective serotonin reuptake inhibitor flu-voxamine in children and adolescents. J Child Adolesc Psycho-pharmacol 19:119-126, 2009.
20. Reinblatt SP, Riddle MA: Selective serotonin reuptake inhibitor-induced apathy: A pediatric case series. J Child Adolesc Psycho-pharmacol 16:227-233, 2006.
21. Research Units for Pediatric Psychopharmacology (RUPP) Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285, 2001.
22. Riddle MA, King R, Hardin MT, Scahill L, Ort S, Chappell P, Ras-musson A, Leckman J: Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1:193198, 1991.
23. Rigoni G: Drug Utilization for Selected Antidepressants Among Children & Adolescents in the U.S. 2004. Available at www.fda.gov/ohrms/dockets/ac/ 04/slides/4006S1-04-Rigoni-files/frame.htm. Accessed July 29, 2009.
24. Rubin RT, Villanueva-Meyer J, Ananth J, Trajmar PG, Mena I: Regional xenon 133 cerebral blood flow and cerebral technetium 99m HMPAO uptake in unmedicated patients with obsessive-compulsive disorder and matched normal control subjects. Determination by high-resolution single-photon emission computed tomography. Arch Gen Psychiatry 49:695-702, 1992.
25. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI: Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 44:495-498, 1997.
26. Starkstein SE, Robinson RG: Mechanism of disinhibition after brain lesions. J Nerv Ment Dis 185:108-114, 1997.
27. Strakowski SM, Adler CM, Cerullo MA, Eliassen JC, Lamy M, Fleck DE, Lee JH, DelBello MP: MRI brain activation in first-episode bipolar mania during a response inhibition task. Early Interv Psychiatry 2:225-233, 2008.
28. Surguladze SA, Marshall N, Schulze K, Hall MH, Walshe M, Bramon E, Phillips ML, Murray RM, McDonald C: Exaggerated neural response to emotional faces in patients with bipolar disorder and their first-degree relatives. Neuroimage 2010 Jun 8 [Epub ahead of print].
29. Walkup J, Labellarte M: Complications of SSRI treatment. J Child Adolesc Psychopharmacol 11:1-4, 2001.
30. Warrington SJ: Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int Clin Psychopharmacol 7(Suppl 2):13-19, 1992.
31. Xu ZH, Xie HG, Zhou HH: In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 42:518-521, 1996.